ReviewFrontiers in oncology2022

Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia.

Kota Yoshifuji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.